MitchellN.DavisDO

PubMed

• 3 citations
  Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection.
  Tarik Asselah, Stephen D. Shafran, Suzanne Bourgeois, Ching-Lung Lai, Philippe Mathurin, Bernard Willems, Mindie H. Nguyen, M. Davis, K.C. Huang, Evguenia S. Svarovska...> ;Journal of Viral Hepatitis. 2019 Oct 1
• 63 citations
  Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
  Edward Gane, Mitchell L. Shiffman, Kyle Etzkorn, Giuseppe Morelli, Catherine A.M. Stedman, M. Davis, Federico Hinestrosa, Hadas Dvory-Sobol, K.C. Huang, Anu Osinusi, J...> ;Hepatology. 2017 Oct 1
• 170 citations
  Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
  Ira M. Jacobson, Eric Lawitz, Edward Gane, Bernard Willems, Peter Ruane, Ronald Nahass, Sergio Borgia, Stephen D. Shafran, Kimberly A. Workowski, Brian L. Pearlman, Ro...> ;Gastroenterology. 2017 Jul 1
• 45 citations
  Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
  Edward Gane, Kris V. Kowdley, David Pound, Catherine A.M. Stedman, M. Davis, K.P. Etzkorn, Stuart C. Gordon, David E. Bernstein, Gregory T. Everson, Maribel Rodríguez-...> ;Gastroenterology. 2016 Nov 1
• 145 citations
  Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study
  Paul Y. Kwo, Norman Gitlin, Ronald Nahass, David E. Bernstein, K.P. Etzkorn, Sergio Rojter, Eugene R. Schiff, M. Davis, Peter Ruane, Ziad Younes, R. Kalmeijer, Rekha S...> ;Hepatology. 2016 Aug 1
• Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
  Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, ...> ;N Engl J Med. 2015 Dec 31
• Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
  Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourliere M, Asselah T, Berg T, ...> ;N Engl J Med. 2015 Dec 31
• 85 citations
  Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial
  Gregory T. Everson, William J. Towner, M. Davis, David L. Wyles, Ronald Nahass, Paul J. Thuluvath, Kyle Etzkorn, Federico Hinestrosa, Myron J. Tong, Mordechai Rabinovi...> ;Annals of Internal Medicine. 2015 Dec 1
• Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
  Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros ...> ;N Engl J Med. 2014 May 15
• Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
  Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Brau N, Buti M, Jacobson IM, Subramanian GM, Din...> ;N Engl J Med. 2014 May 15
• 36 citations
  Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
  , , , , , , , , , , , , , , , , , , , , , > ;Journal of Hepatology. 2014 Apr 1
• Join now to see all